In addition, a positive trend in the reduction of BPD was observed in the treated group (44%) compared to the control group (70%). 75 In a recent phase 2 trial with rhIGF-1/rhIGFBP-3 supplementation, a decreased occurrence of severe BPD in preterm infants ( n = 61, GA: 23–27 + 6/7 weeks) was also confirmed. 102 In summary, recent studies using IGF-1 show a trend towards improved growth and reduced neonatal morbidities in preterm infants.
← all excerpts
Metabolic-endocrine disruption due to preterm birth impacts growth, body composition, and neonatal outcome.
1
—
—